Faruqi & Faruqi, LLP Urges Unicycive Therapeutics, Inc. (UNCY) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class Action Ready to Announce with Confidence?
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Unicycive to Contact Him Directly to Discuss Their Options
New York, New York--(Newsfile Corp. - September 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY).
[You may also click here for additional information]
WHY: Faruqi & Faruqi, LLP, a leading national securities law firm, informs investors of the federal securities class action on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026, inclusive (the "Class Period").
WHAT TO DO NEXT: To learn more about the Unicycive class action, go to www.faruqilaw.com/UNCY or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). A class action lawsuit has already been filed.
If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
THE ALLEGATIONS:
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company had not inspected its third-party manufacturing vendor's facility or otherwise audited the facility's compliance with current good manufacturing practices; (2) that, as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA's cited deficiencies; (3) that there was an undisclosed risk that the FDA would require additional information about the vendor's facility's manufacturing practices; (4) that, as a result of the foregoing, the regulatory approval of OLC was reasonably likely to be delayed; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Unicycive's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Frequently Asked Questions (FAQ) for Investors Regarding the Unicycive Securities Class Action Lawsuit
Who may be eligible to participate in the lawsuit?
Investors who purchased or acquired Unicycive (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
How much did Unicycive stock drop?
Following the alleged corrective disclosures, Unicycive shares fell approximately 39.1% on June 30, 2026, as described in the complaint.
Why should investors contact Faruqi & Faruqi, LLP?
Faruqi & Faruqi, LLP is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. Faruqi & Faruqi, LLP has represented investors in securities litigation for decades and has recovered hundreds of millions of dollars for shareholders. Investors who purchased Unicycive Therapeutics, Inc. securities during the Class Period may contact the firm to discuss their legal rights, potential claims, and the lead plaintiff process at no cost or obligation.
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/316062
Source: Faruqi & Faruqi LLP
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Faruqi & Faruqi LLP or all companies in the Banking / Financial Services industry.
Faruqi & Faruqi, LLP Urges Unicycive Therapeutics, Inc. (UNCY) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class Action
2026-09-27 9:34 AM EDT
Faruqi & Faruqi, LLP Urges Blaize Holdings (BZAI) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action
2026-09-27 9:24 AM EDT
HIMS INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Hims Investors of Securities Class Action Lawsuit Deadline on November 2, 2026
2026-09-26 10:09 AM EDT
Jun 29, 2026
For many public issuers, expanding into new markets means more to manage. As disclosure extends across Canada and the United States, even core tasks like distributing and posting press releases can involve additional steps, systems, and coordination. For DLP Resources Inc., a publicly traded mineral exploration company, the focus has been on keeping the distribution and cross-border posting of its news simple. “They seamlessly post our news on the OTC Markets site. I don’t even have to think...
Litigation and Regulation
Banking / Financial Services